| Name | Title | Contact Details |
|---|
Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla`s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world`s first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics.
Applegarth Care Ctr is a Monroe Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.
For decades, entrenched infrastructure barriers have slowed progress in the fight against cancer and the development of potent immunotherapies. The Parker Institute for Cancer Immunotherapy breaks down these barriers. The result is groundbreaking new research and an intellectual property model that builds collaboration between researchers, nonprofits and industry all working together to get treatments to patients faster.
MedOne unlocks the most appropriate prescription at the most affordable price for organizations and their health plan members nationwide. The MedOne model delivers real prescription savings by cutting out the traditional "PBM" middlemen and facilitating direct relationships between health plans and high-performing pharmacies. Once we establish a transparent and aligned marketplace, we partner with organizations to optimize "where" and "what" members fill to reduce pharmacy costs and improve health outcomes. Ready for a new approach to pharmacy benefits? We invite you to experience the difference!